Gain Therapeutics, Inc. (GANX) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Gain Therapeutics, Inc. (GANX) Earnings Overview
As of June 29, 2026, Gain Therapeutics, Inc. (GANX) reported trailing twelve-month net income of -$21M, reflecting +31.5% year-over-year growth. The company earned $-0.50 per diluted share over the past four quarters.
Looking at the long-term picture, GANX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2018.
Gain Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ACMR ($91M net income, 10.4% margin), RARE (-$609M net income, -85.4% margin), GANX has comparable earnings metrics. Compare GANX vs PRAX →
GANX Earnings vs Peers
Earnings metrics vs comparable public companies
GANX Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | +1.2% | -$19M | $-0.61 | - | - |
| 2024 | -$20M | +8.3% | -$20M | $-0.89 | - | - |
| 2023 | -$22M | -26.6% | -$22M | $-1.71 | -40354.3% | -40328.3% |
| 2022 | -$18M | -26.6% | -$18M | $-1.48 | -12555.1% | -12688.1% |
| 2021 | -$14M | -288.3% | -$14M | $-1.37 | -8418.9% | -8379.8% |
| 2020 | -$4M | -63.1% | -$3M | $-0.30 | -12387.7% | -12047.5% |
| 2019 | -$2M | -98.4% | -$2M | $-0.26 | -5310.9% | -5084.9% |
| 2018 | -$1M | - | -$1M | $-0.19 | -5364.4% | -4989.7% |
Download Data
Export GANX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GANX — Frequently Asked Questions
Quick answers to the most common questions about buying GANX stock.
What is GANX earnings per share (EPS)?
GANX trailing twelve-month (TTM) diluted EPS is $-0.50, reflecting +31.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Gain Therapeutics, Inc.'s net income?
Gain Therapeutics, Inc. (GANX) trailing twelve-month net income is $-21M as of 2025. Earnings grew +31.5% year-over-year.
Is GANX profitable?
GANX is not currently profitable on a TTM basis, reporting a net loss of $-21M. Net margin is N/A. Investors should monitor for a return to profitability.
What is GANX's earnings growth rate?
GANX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are GANX's profit margins?
Gain Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -155.7%.
Is GANX growing earnings?
Yes, GANX earnings are accelerating — EPS growth of +31.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-21M. Earnings momentum is strengthening.
What was GANX's best earnings year?
Gain Therapeutics, Inc.'s highest annual net income on record is $-1M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were GANX's earnings last quarter?
GANX's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.13. For a full breakdown of all quarters, see the quarterly earnings table on this page.